Phibro Animal Health (NASDAQ:PAHC) Hits New 1-Year High – Should You Buy?

Phibro Animal Health Corporation (NASDAQ:PAHC)’s stock price reached a new 52-week high during trading on Wednesday . The stock traded as high as $58.84 and last traded at $58.1680, with a volume of 329 shares changing hands. The stock had previously closed at $55.66.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on PAHC shares. Morgan Stanley set a $49.00 price target on shares of Phibro Animal Health in a report on Friday, February 6th. Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 11th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $37.50.

Phibro Animal Health Stock Performance

The business’s 50-day moving average price is $51.09 and its 200-day moving average price is $44.10. The company has a current ratio of 3.05, a quick ratio of 1.22 and a debt-to-equity ratio of 2.14. The stock has a market cap of $2.37 billion, a PE ratio of 26.06, a P/E/G ratio of 0.85 and a beta of 0.69.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.18. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. The firm had revenue of $373.91 million for the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. As a group, equities research analysts expect that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th were given a $0.12 dividend. The ex-dividend date of this dividend was Wednesday, March 4th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 0.8%. Phibro Animal Health’s payout ratio is presently 21.33%.

Insider Activity

In other Phibro Animal Health news, CEO Jack Bendheim sold 110,842 shares of the business’s stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $48.38, for a total transaction of $5,362,535.96. Following the sale, the chief executive officer owned 122,958 shares of the company’s stock, valued at approximately $5,948,708.04. The trade was a 47.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last quarter, insiders have sold 316,472 shares of company stock valued at $15,265,419. 50.13% of the stock is owned by insiders.

Institutional Trading of Phibro Animal Health

Several large investors have recently bought and sold shares of the stock. 1620 Investment Advisors Inc. grew its position in Phibro Animal Health by 77.4% during the 4th quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock worth $25,000 after purchasing an additional 295 shares during the last quarter. Tudor Investment Corp ET AL grew its position in Phibro Animal Health by 3.4% during the 3rd quarter. Tudor Investment Corp ET AL now owns 10,184 shares of the company’s stock worth $412,000 after purchasing an additional 338 shares during the last quarter. JPMorgan Chase & Co. grew its position in Phibro Animal Health by 2.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock worth $332,000 after purchasing an additional 363 shares during the last quarter. Farther Finance Advisors LLC grew its position in Phibro Animal Health by 113.2% during the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after purchasing an additional 386 shares during the last quarter. Finally, Brooklyn Investment Group grew its position in Phibro Animal Health by 8.7% during the 4th quarter. Brooklyn Investment Group now owns 6,757 shares of the company’s stock worth $255,000 after purchasing an additional 538 shares during the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.